Verastem (VSTM) Competitors

$4.26 -0.06 (-1.39%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$4.31 +0.05 (+1.17%)

As of 05/18/2026 07:59 PM Eastern

VSTM vs. INVA, NVAX, ZBIO, MNKD, and GERN

Should you buy Verastem stock or one of its competitors? MarketBeat compares Verastem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verastem include Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), MannKind (MNKD), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Verastem compare to Innoviva?

Verastem (NASDAQ:VSTM) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Innoviva has a net margin of 119.89% compared to Verastem's net margin of -391.17%. Innoviva's return on equity of 33.33% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Innoviva	119.89%	33.33%	22.67%

Verastem presently has a consensus target price of $15.60, suggesting a potential upside of 266.20%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 66.06%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts clearly believe Verastem is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	12.11	-$209.47M	-$2.70	N/A
Innoviva	$411.33M	3.91	$271.17M	$6.01	3.63

In the previous week, Verastem and Verastem both had 2 articles in the media. Innoviva's average media sentiment score of 0.64 beat Verastem's score of 0.30 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

88.4% of Verastem shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Innoviva beats Verastem on 11 of the 16 factors compared between the two stocks.

How does Verastem compare to Novavax?

Novavax (NASDAQ:NVAX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Novavax has higher revenue and earnings than Verastem. Novavax is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$596.34M	2.46	$440.30M	-$0.58	N/A
Verastem	$30.91M	12.11	-$209.47M	-$2.70	N/A

Novavax has a net margin of -14.73% compared to Verastem's net margin of -391.17%. Novavax's return on equity of -14.82% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Verastem	-391.17%	-486.40%	-91.56%

53.0% of Novavax shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Novavax had 6 more articles in the media than Verastem. MarketBeat recorded 8 mentions for Novavax and 2 mentions for Verastem. Novavax's average media sentiment score of 0.74 beat Verastem's score of 0.30 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Verastem has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 35.78%. Verastem has a consensus price target of $15.60, suggesting a potential upside of 266.20%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Novavax beats Verastem on 9 of the 17 factors compared between the two stocks.

How does Verastem compare to Zenas BioPharma?

Verastem (NASDAQ:VSTM) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

88.4% of Verastem shares are held by institutional investors. 1.9% of Verastem shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Zenas BioPharma	N/A	-99.99%	-58.06%

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	12.11	-$209.47M	-$2.70	N/A
Zenas BioPharma	$10M	106.75	-$377.74M	-$8.47	N/A

Verastem presently has a consensus price target of $15.60, suggesting a potential upside of 266.20%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 161.89%. Given Verastem's stronger consensus rating and higher probable upside, research analysts clearly believe Verastem is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Verastem has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, suggesting that its share price is 161% less volatile than the broader market.

In the previous week, Zenas BioPharma had 12 more articles in the media than Verastem. MarketBeat recorded 14 mentions for Zenas BioPharma and 2 mentions for Verastem. Zenas BioPharma's average media sentiment score of 0.86 beat Verastem's score of 0.30 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Verastem beats Zenas BioPharma on 10 of the 17 factors compared between the two stocks.

How does Verastem compare to MannKind?

MannKind (NASDAQ:MNKD) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, MannKind had 10 more articles in the media than Verastem. MarketBeat recorded 12 mentions for MannKind and 2 mentions for Verastem. MannKind's average media sentiment score of 0.88 beat Verastem's score of 0.30 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Verastem has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

MannKind presently has a consensus price target of $8.84, suggesting a potential upside of 195.78%. Verastem has a consensus price target of $15.60, suggesting a potential upside of 266.20%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Verastem	-391.17%	-486.40%	-91.56%

49.6% of MannKind shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	2.65	$5.86M	-$0.07	N/A
Verastem	$30.91M	12.11	-$209.47M	-$2.70	N/A

Summary

MannKind beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Geron?

Verastem (NASDAQ:VSTM) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Geron has a net margin of -35.48% compared to Verastem's net margin of -391.17%. Geron's return on equity of -23.31% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Geron	-35.48%	-23.31%	-10.08%

Verastem presently has a consensus target price of $15.60, suggesting a potential upside of 266.20%. Geron has a consensus target price of $2.50, suggesting a potential upside of 103.25%. Given Verastem's stronger consensus rating and higher probable upside, equities research analysts plainly believe Verastem is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Geron had 2 more articles in the media than Verastem. MarketBeat recorded 4 mentions for Geron and 2 mentions for Verastem. Geron's average media sentiment score of 0.86 beat Verastem's score of 0.30 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.4% of Verastem shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Verastem has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Geron has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Geron has higher revenue and earnings than Verastem. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	12.11	-$209.47M	-$2.70	N/A
Geron	$183.88M	4.29	-$83.50M	-$0.11	N/A

Summary

Geron beats Verastem on 9 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$379.61M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-1.58	18.13	20.86	25.23
Price / Sales	12.11	275.96	550.91	75.54
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	5.76	6.57	9.67	6.63
Net Income	-$209.47M	$24.35M	$3.56B	$335.59M
7 Day Performance	-7.99%	-2.53%	-1.69%	-1.20%
1 Month Performance	-35.26%	-3.55%	-2.65%	-1.16%
1 Year Performance	-45.03%	53.51%	30.03%	28.10%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	2.8695 of 5 stars	$4.26 -1.4%	$15.60 +266.2%	-43.9%	$379.61M	$30.91M	N/A	50
INVA Innoviva	3.8172 of 5 stars	$22.52 -1.6%	$36.20 +60.7%	+17.3%	$1.70B	$411.33M	3.75	100	Analyst Downgrade
NVAX Novavax	1.9652 of 5 stars	$9.50 -6.0%	$12.13 +27.6%	+32.7%	$1.66B	$1.12B	N/A	1,990	Gap Up High Trading Volume
ZBIO Zenas BioPharma	3.5404 of 5 stars	$20.40 +3.9%	$44.14 +116.4%	+61.5%	$1.13B	$10M	N/A	N/A	News Coverage Earnings Report Analyst Upgrade Insider Trade
MNKD MannKind	3.9734 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-31.6%	$1.09B	$348.97M	N/A	400	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors